Hikma And CanariaBio Sign Exclusive Licensing Agreement To Bring Oregovomab To The Middle East And North Africa
By Emmanuel Oluebube, Bureau Chief, UK The multinational pharmaceutical company, Hikma Pharmaceuticals PLC(Hikma), today announced an exclusive license agreement with CanariaBio, a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. Under the terms of the agreement, Hikma has an exclusive license to commercialise Oregovomabin 18Middle...